Regeneron Pharmaceuticals debt and dilution—

Borrowings, liquidity, share count and stock-based dilution.

Total debt

USD millions

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Cash & equivalents

USD millions

$2,455.8M

Net debt

USD millions

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Debt / equity

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Debt / assets

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Net debt / EBITDA

× · TTM

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Debt / FCF

× · TTM

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Interest coverage

× · TTM

69.37×

Current ratio

3.34×

Diluted shares

Million shares

106M shares

Basic shares

Million shares

102.8M shares

Share count growth

-2.19%

Share repurchases

USD millions

$1,169.4M

Quarterly data

Regeneron Pharmaceuticals capital history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal period	Ended	Total debtUSD millions	Cash & equivalentsUSD millions	Net debtUSD millions	Debt / equity×	Debt / assets%	Net debt / EBITDA×	Debt / FCF×	Interest coverage×	Current ratio×	Diluted sharesMillion shares	Basic sharesMillion shares	Share count growth%	Share repurchasesUSD millions
FY 2026 Q2	Jun 30, 2026	—	2,455.8	—	—	—	—	—	69.37×	3.34×	106	102.8	-2.19%	1,169.4
FY 2026 Q1	Mar 31, 2026	—	2,962.6	—	—	—	—	—	75.61×	3.57×	107.7	104	-2.53%	794.3
FY 2025 Q4	Dec 31, 2025	—	3,118.1	—	—	—	—	—	81.69×	4.13×	107.71	103.12	-4.17%	671.7
FY 2025 Q3	Sep 30, 2025	—	2,506.4	—	—	—	—	—	87.61×	4.06×	107.2	103.6	-4.16%	664
FY 2025 Q2	Jun 30, 2025	—	1,995.8	—	—	—	—	—	104.94×	4.6×	108.6	105.1	-2.78%	1,061.5
FY 2025 Q1	Mar 31, 2025	—	3,090.2	—	—	—	—	—	80.15×	4.93×	111.2	106.7	-1.02%	1,041.4
FY 2024 Q4	Dec 31, 2024	—	2,488.2	—	—	—	—	—	72.3×	4.73×	113.61	107.6	1.13%	973
FY 2024 Q3	Sep 30, 2024	—	2,011.8	—	—	—	—	—	63.07×	5.28×	116.2	108.1	1.69%	735.1
FY 2024 Q2	Jun 30, 2024	—	1,920.7	—	—	—	—	—	58.28×	5.44×	115.4	108.1	1.03%	603.9
FY 2024 Q1	Mar 31, 2024	—	2,602	—	—	—	—	—	54.17×	5.27×	115.1	107.8	0.65%	291.3
FY 2023 Q4	Dec 31, 2023	—	2,730	—	—	—	—	—	55.44×	5.69×	113.7	106.4	-0.37%	289
FY 2023 Q3	Sep 30, 2023	—	2,152.3	—	—	—	—	—	58.54×	5.18×	113.4	106.3	-0.56%	546.5
FY 2023 Q2	Jun 30, 2023	—	1,937.2	—	—	—	—	—	62.27×	5.45×	113.9	107	-0.83%	688.8
FY 2023 Q1	Mar 31, 2023	—	3,916.3	—	—	—	—	—	69.39×	5.45×	114	107.1	0.28%	710.7
FY 2022 Q4	Dec 31, 2022	—	3,105.9	—	—	—	—	—	79.78×	5.06×	114.09	106.8	0.48%	431.1
FY 2022 Q3	Sep 30, 2022	—	3,491.3	—	—	—	—	—	111.08×	5.36×	112.8	106.9	0.66%	934.6
FY 2022 Q2	Jun 30, 2022	—	3,395.1	—	—	—	—	—	124.64×	5.12×	114	107.9	2.76%	359
FY 2022 Q1	Mar 31, 2022	—	3,345.7	—	—	—	—	—	161.5×	4.76×	113.1	106.8	1.33%	358.1
FY 2021 Q4	Dec 31, 2021	—	2,885.6	—	—	—	—	—	156.14×	3.56×	113.39	106.29	0.74%	866.9
FY 2021 Q3	Sep 30, 2021	—	3,432.4	—	—	—	—	—	128.86×	3.71×	113.9	106.2	0.66%	166.4
FY 2021 Q2	Jun 30, 2021	—	2,072.2	—	—	—	—	—	95.29×	3.57×	110.8	105	-4.2%	305.2
FY 2021 Q1	Mar 31, 2021	—	1,437.9	—	—	—	—	—	61×	3.12×	110.5	105.4	-4.01%	306.9
FY 2020 Q4	Dec 31, 2020	—	2,193.7	—	—	—	—	—	62.86×	3.63×	112.12	105.52	-3.37%	381.1
FY 2020 Q3	Sep 30, 2020	—	1,573	—	—	—	—	—	63.22×	3.89×	113.9	105.5	-3.56%	92.1
FY 2020 Q2	Jun 30, 2020	—	1,992.2	—	—	—	—	—	91.44×	2.12×	117.9	109.6	0.37%	5,052.9
FY 2020 Q1	Mar 31, 2020	—	2,208.2	—	—	—	—	—	84.96×	4.21×	115.1	109.8	0.83%	320.7
FY 2019 Q4	Dec 31, 2019	—	1,617.8	—	—	—	—	—	73.17×	3.67×	114.3	109.2	1%	246.5
FY 2019 Q3	Sep 30, 2019	—	1,384.8	—	—	—	—	—	73.01×	4.03×	114.2	109.4	1.27%	19.4
FY 2019 Q2	Jun 30, 2019	—	1,045.5	—	—	—	—	—	70.08×	3.88×	114.6	109.2	1.3%	0
FY 2019 Q1	Mar 31, 2019	—	1,708.5	—	—	—	—	—	83.06×	4.58×	115.5	108.9	1.16%	10
FY 2018 Q4	Dec 31, 2018	—	1,467.7	—	—	—	—	—	89.87×	4.47×	114.67	108.11	1.02%	0.02
FY 2018 Q3	Sep 30, 2018	—	1,087.84	—	—	—	—	—	87.66×	4.04×	115.09	108.03	1.24%	4.38
FY 2018 Q2	Jun 30, 2018	—	917.88	—	—	—	—	—	89.54×	3.62×	114.48	107.8	1.67%	0
FY 2018 Q1	Mar 31, 2018	—	1,019.49	—	—	—	—	—	92.2×	3.59×	114.91	107.65	1.97%	0
FY 2017 Q4	Dec 31, 2017	—	812.73	—	—	—	—	—	82.85×	3.82×	115.84	107.02	1.81%	0
FY 2017 Q3	Sep 30, 2017	—	792.07	—	—	—	—	—	—	3.63×	117.03	106.71	1.79%	—
FY 2017 Q2	Jun 30, 2017	—	744.31	—	—	—	—	—	—	3.75×	116.14	106.03	1.34%	—
FY 2017 Q1	Mar 31, 2017	—	811.77	—	—	—	—	—	—	2.8×	115.11	105.57	1.23%	—
FY 2016 Q4	Dec 31, 2016	—	535.2	—	—	—	—	—	184.83×	2.56×	115.77	105.12	1.3%	—
FY 2016 Q3	Sep 30, 2016	—	920.36	—	—	—	—	—	—	3.64×	116.47	104.83	1.44%	—
FY 2016 Q2	Jun 30, 2016	—	646.51	—	—	—	—	—	—	3.37×	116.23	104.63	1.7%	—
FY 2016 Q1	Mar 31, 2016	—	604.21	—	—	—	—	—	—	3.41×	114.23	104.29	2.02%	—
FY 2015 Q4	Dec 31, 2015	—	809.1	—	—	—	—	—	87.91×	3.59×	115.49	103.76	2.26%	—
FY 2015 Q3	Sep 30, 2015	—	654.59	—	—	—	—	—	72.82×	3.64×	115.94	103.35	2.53%	—
FY 2015 Q2	Jun 30, 2015	—	390.55	—	—	—	—	—	41.92×	3.8×	115.26	102.89	2.49%	—
FY 2015 Q1	Mar 31, 2015	—	507.91	—	—	—	—	—	28.33×	4.31×	114.52	102.23	3.56%	—
FY 2014 Q4	Dec 31, 2014	—	648.72	—	—	—	—	—	22.05×	3.31×	114.04	101.46	2.64%	—
FY 2014 Q3	Sep 30, 2014	—	646.55	—	—	—	—	—	18.82×	5.36×	117.42	100.8	2.62%	—
FY 2014 Q2	Jun 30, 2014	—	600.14	—	—	—	—	—	18.97×	5.46×	113.03	100.39	2.75%	—
FY 2014 Q1	Mar 31, 2014	—	461.86	—	—	—	—	—	17.1×	6.13×	112.15	98.71	1.89%	—
FY 2013 Q4	Dec 31, 2013	—	535.61	—	—	—	—	—	16.37×	6.01×	98.64	98.85	3.31%	—
FY 2013 Q3	Sep 30, 2013	—	263.21	—	—	—	—	—	14.99×	6.08×	116.71	98.23	3.38%	—
FY 2013 Q2	Jun 30, 2013	—	381.68	—	—	—	—	—	14.35×	7.66×	111.06	97.7	3.29%	—
FY 2013 Q1	Mar 31, 2013	—	180.36	—	—	—	—	—	12.85×	6.63×	109.37	96.88	3.67%	—
FY 2012 Q4	Dec 31, 2012	—	230.28	—	—	—	—	—	10.1×	7.37×	132.07	95.69	4.25%	—
FY 2012 Q3	Sep 30, 2012	—	119	—	—	—	—	—	6.16×	5.31×	115.83	95.01	4.36%	—
FY 2012 Q2	Jun 30, 2012	—	171.94	—	—	—	—	—	0.16×	4.2×	110.17	94.59	4.59%	—
FY 2012 Q1	Mar 31, 2012	—	394.59	—	—	—	—	—	-4.94×	4.35×	107.73	93.45	4.8%	—
FY 2011 Q4	Dec 31, 2011	—	483.61	—	—	—	—	—	-9.64×	4.4×	91.78	91.78	—	—
FY 2011 Q3	Sep 30, 2011	—	206.4	—	—	—	—	—	-12.08×	2.55×	91.05	91.05	—	—
FY 2011 Q2	Jun 30, 2011	—	254.31	—	—	—	—	—	-11.73×	3.04×	90.44	90.44	—	—
FY 2011 Q1	Mar 31, 2011	—	135.38	—	—	—	—	—	-10.19×	2.9×	89.16	89.16	—	—
FY 2010 Q4	Dec 31, 2010	—	112.57	—	—	—	—	—	-10.69×	3.28×	—	—	—	—
FY 2010 Q3	Sep 30, 2010	—	325.29	—	—	—	—	—	—	4.3×	—	—	—	—
FY 2010 Q2	Jun 30, 2010	—	112	—	—	—	—	—	—	3.49×	—	—	—	—

Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Debt uses reported borrowings, with overlapping concepts treated as alternatives. Cash excludes restricted cash and short-term investments. Dilution compares split-normalized weighted average basic shares year over year. Share buyback spending does not by itself measure shares retired.

Market prices: Yahoo Finance · REGN, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Total debt: Reported borrowing balances. Uses an aggregate including current maturities, or current plus noncurrent debt. Adds separately disclosed short-term borrowings, with commercial paper as a fallback, unless the selected current/aggregate concept already includes them. Finance leases are included when part of the reported debt concept; undisclosed components are not estimated.
Cash & equivalents: Unrestricted reported cash and cash equivalents. Excludes short-term investments and restricted cash.
Net debt: Total debt − cash and equivalents. Negative means net cash.
Debt / equity: Total debt / equity including noncontrolling interests. Nonpositive equity yields unavailable.
Debt / assets: Total debt / total assets × 100.
Net debt / EBITDA: Period-end net debt / (TTM operating income + TTM depreciation and amortization). Negative net debt is retained.
Debt / FCF: Period-end reported debt / positive TTM free cash flow. Reflects the selected reported capex scope and SBC option.
Interest coverage: TTM operating income / positive TTM interest expense. IFRS finance costs can include more than interest.
Current ratio: Current assets / positive current liabilities.
Diluted shares: Reported weighted average diluted shares, normalized for subsequent recorded stock splits. Fourth-quarter counts use a day-weighted annual/nine-month reconstruction where possible.
Basic shares: Reported weighted average basic shares, normalized for subsequent recorded stock splits.
Share count growth: Year-over-year change in split-normalized weighted average basic shares × 100. A dilution proxy; negative means a lower share count.
Share repurchases: Reported cash payments for repurchase of common shares. This is spending, not a buyback yield.